CVS Quote, Financials, Valuation and Earnings

Biogen has a net margin of 1.88% compared to CVS Health's net margin of 9.89%. CVS Health's return on equity of 7% beat Biogen's return on equity of 9.11%.

CVS Health has a consensus price target of $79.09, signalling upside risk potential of 16.56%. On the other hand Biogen has an analysts' consensus of $172.25 which suggests that it could grow by 45.49%. Given that Biogen has higher upside potential than CVS Health, analysts believe Biogen is more attractive than CVS Health.

CVS Health has a beta of 0.598, which suggesting that the stock is 40.158% less volatile than S&P 500. In comparison Biogen has a beta of 0.125, suggesting its less volatile than the S&P 500 by 87.479%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 3.92%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVS Health pays 73.1% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $94.6B, which are larger than Biogen quarterly revenues of $2.4B. CVS Health's net income of $1.8B is higher than Biogen's net income of $240.5M. Notably, CVS Health's price-to-earnings ratio is 16.19x while Biogen's PE ratio is 11.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.23x versus 1.76x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 1.88% compared to CVS Health's net margin of 19.72%. CVS Health's return on equity of 7% beat Gilead Sciences's return on equity of 32.29%.

CVS Health has a consensus price target of $79.09, signalling upside risk potential of 16.56%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 17.19%. Given that Gilead Sciences has higher upside potential than CVS Health, analysts believe Gilead Sciences is more attractive than CVS Health.

CVS Health has a beta of 0.598, which suggesting that the stock is 40.158% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 3.92%. Gilead Sciences offers a yield of 3.16% to investors and pays a quarterly dividend of $0.79 per share. CVS Health pays 73.1% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

CVS Health quarterly revenues are $94.6B, which are larger than Gilead Sciences quarterly revenues of $6.7B. CVS Health's net income of $1.8B is higher than Gilead Sciences's net income of $1.3B. Notably, CVS Health's price-to-earnings ratio is 16.19x while Gilead Sciences's PE ratio is 20.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.23x versus 4.31x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Humana has a net margin of 1.88% compared to CVS Health's net margin of 3.87%. CVS Health's return on equity of 7% beat Humana's return on equity of 10.08%.

CVS Health has a consensus price target of $79.09, signalling upside risk potential of 16.56%. On the other hand Humana has an analysts' consensus of $309.40 which suggests that it could grow by 22.12%. Given that Humana has higher upside potential than CVS Health, analysts believe Humana is more attractive than CVS Health.

CVS Health has a beta of 0.598, which suggesting that the stock is 40.158% less volatile than S&P 500. In comparison Humana has a beta of 0.494, suggesting its less volatile than the S&P 500 by 50.63%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 3.92%. Humana offers a yield of 1.4% to investors and pays a quarterly dividend of $0.89 per share. CVS Health pays 73.1% of its earnings as a dividend. Humana pays out 35.71% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $94.6B, which are larger than Humana quarterly revenues of $32.1B. CVS Health's net income of $1.8B is higher than Humana's net income of $1.2B. Notably, CVS Health's price-to-earnings ratio is 16.19x while Humana's PE ratio is 17.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.23x versus 0.25x for Humana. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 1.88% compared to CVS Health's net margin of -907.48%. CVS Health's return on equity of 7% beat Moderna's return on equity of -29.23%.

CVS Health has a consensus price target of $79.09, signalling upside risk potential of 16.56%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 92.62%. Given that Moderna has higher upside potential than CVS Health, analysts believe Moderna is more attractive than CVS Health.

CVS Health has a beta of 0.598, which suggesting that the stock is 40.158% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 3.92%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVS Health pays 73.1% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $94.6B, which are larger than Moderna quarterly revenues of $107M. CVS Health's net income of $1.8B is higher than Moderna's net income of -$971M. Notably, CVS Health's price-to-earnings ratio is 16.19x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.23x versus 3.02x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.